Lijing Ma1,2, Jiaxin Xu3, Qisheng Tang4, Yu Cao5,6, Ruize Kong7,8, Kunlin Li3, Jie Liu4, Lihong Jiang5,6. 1. Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China. 2. Department of Endocrinology, The First People's Hospital of Yunnan Province, Kunming, China. 3. Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China. 4. Regenerative Medicine Research Center, The First People's Hospital of Yunnan Province, Kunming, China. 5. Department of Cardiovascular Surgery, The First Peoples' Hospital of Yunnan Province, Kunming, China. 6. Department of Cardiovascular Surgery, The First Affiliated Hospital of Kunming University of Science and Technology, Kunming, China. 7. Department of Vascular Surgery, The First Peoples' Hospital of Yunnan Province, Kunming, China. 8. Department of Vascular Surgery, The First Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Abstract
BACKGROUND: Solute carrier family 2 member 3 (SLC2A3), is a member of a superfamily of transport protein genes. SLC2A3 played an important role in embryonic development. Previous research reported SLC2A3 duplication was reportedly associated with congenital syndromic heart defects. However, it is not clear whether the gene is associated with non-syndromic congenital heart disease. Our study aimed to elucidate the relationship between its variation and congenital heart disease. METHODS: Genomic DNA extracted from the peripheral blood leukocytes of two families with CHD were sequenced with whole-exome sequencing to identify variations, used Sanger sequencing to investigate SLC2A3 variants in 494 Chinese patients with CHD and 576 healthy unrelated individuals. RESULTS: In members from the two families, three with CHD had the SLC2A3 (rs3931701) C > T variant. Of the 494 patients with CHD, 394 had gene variants (86 had the TT type and 308 had the CT type). Of the 576 healthy controls, 272 participants had gene variants (36 had the TT type and 236 had the CT type). The TT type [p < 0.0001, odds ratio (OR) =7.262, 95% confidence interval (CI) =4.631-11.388] and CT type (p < 0.0001, OR =3.967, 95% CI =2.991-5.263) of SLC2A3 (rs3931701) significantly increased the risk of sporadic ASD in a Chinese Yunnan population. CONCLUSIONS: Single nucleotide variations of SLC2A3, particularly, the SLC2A3 (rs3931701) C > T variant increased the risk of CHD among the studied population.
BACKGROUND: Solute carrier family 2 member 3 (SLC2A3), is a member of a superfamily of transport protein genes. SLC2A3 played an important role in embryonic development. Previous research reported SLC2A3 duplication was reportedly associated with congenital syndromic heart defects. However, it is not clear whether the gene is associated with non-syndromic congenital heart disease. Our study aimed to elucidate the relationship between its variation and congenital heart disease. METHODS: Genomic DNA extracted from the peripheral blood leukocytes of two families with CHD were sequenced with whole-exome sequencing to identify variations, used Sanger sequencing to investigate SLC2A3 variants in 494 Chinese patients with CHD and 576 healthy unrelated individuals. RESULTS: In members from the two families, three with CHD had the SLC2A3 (rs3931701) C > T variant. Of the 494 patients with CHD, 394 had gene variants (86 had the TT type and 308 had the CT type). Of the 576 healthy controls, 272 participants had gene variants (36 had the TT type and 236 had the CT type). The TT type [p < 0.0001, odds ratio (OR) =7.262, 95% confidence interval (CI) =4.631-11.388] and CT type (p < 0.0001, OR =3.967, 95% CI =2.991-5.263) of SLC2A3 (rs3931701) significantly increased the risk of sporadic ASD in a Chinese Yunnan population. CONCLUSIONS: Single nucleotide variations of SLC2A3, particularly, the SLC2A3 (rs3931701) C > T variant increased the risk of CHD among the studied population.
Authors: K-P Lesch; S Selch; T J Renner; C Jacob; T T Nguyen; T Hahn; M Romanos; S Walitza; S Shoichet; A Dempfle; M Heine; A Boreatti-Hümmer; J Romanos; S Gross-Lesch; H Zerlaut; T Wultsch; S Heinzel; M Fassnacht; A Fallgatter; B Allolio; H Schäfer; A Warnke; A Reif; H-H Ropers; R Ullmann Journal: Mol Psychiatry Date: 2010-03-23 Impact factor: 15.992
Authors: Edwin P Kirk; Margaret Sunde; Mauro W Costa; Scott A Rankin; Orit Wolstein; M Leticia Castro; Tanya L Butler; Changbaig Hyun; Guanglan Guo; Robyn Otway; Joel P Mackay; Leigh B Waddell; Andrew D Cole; Christopher Hayward; Anne Keogh; Peter Macdonald; Lyn Griffiths; Diane Fatkin; Gary F Sholler; Aaron M Zorn; Michael P Feneley; David S Winlaw; Richard P Harvey Journal: Am J Hum Genet Date: 2007-06-15 Impact factor: 11.025
Authors: J J Schott; D W Benson; C T Basson; W Pease; G M Silberbach; J P Moak; B J Maron; C E Seidman; J G Seidman Journal: Science Date: 1998-07-03 Impact factor: 47.728
Authors: Trevor P Fidler; Robert A Campbell; Trevor Funari; Nicholas Dunne; Enrique Balderas Angeles; Elizabeth A Middleton; Dipayan Chaudhuri; Andrew S Weyrich; E Dale Abel Journal: Cell Rep Date: 2017-11-07 Impact factor: 9.423
Authors: S Schmidt; A Hommel; V Gawlik; R Augustin; N Junicke; S Florian; M Richter; D J Walther; D Montag; H-G Joost; A Schürmann Journal: J Endocrinol Date: 2008-10-23 Impact factor: 4.286